-
The oral presentation will highlight new data in the Early Access Program (EAP) for acute graft-versus-host disease (aGvHD) patients treated with MaaT013.
-
This is the seventh year that MaaT Pharma's abstracts have been selected for presentation at the EBMT Annual Meeting, confirming the company's leadership in the hemato-oncology/microbiome field.
Lyon, France, March 12, 2024–(BUSINESS WIRE)–Regulatory news:
MaaT Pharma (EURONEXT: MAAT – “the Company”) is a clinical-stage biotechnology company and a leader in the development of microbiome ecosystem therapies.TM Specialized in Improving Cancer Patient Survival (MET) presents expanded results of early access program for aGvHD patients treated with MaaT013 and first 12-month overall survival data for more patients present. Data will be shared during an oral presentation at the 50th Annual Meeting.th The European Society of Blood and Marrow Transplantation Annual Meeting will be held in Glasgow, UK from 14th to 17th April 2024. Details of the presentation will be published in a press release on April 17th.th2024, pursuant to the Conference Embargo Policy.
In line with our mission to improve survival rates for cancer patients, MaaT Pharma has been actively participating in EAP in Europe since 2019. The company has consistently presented real-world data from his EAPs at major hematology conferences over the past four years. EAP results at each data communication point support previous findings that MaaT013 impacts overall survival (OS) if the primary endpoint (GI overall response rate at D28) is achieved ( (See press release for data presented at 2023 ASH)[1] annual meeting). To date, more than 220 patients have been treated with MaaT013 in clinical trials and EAPs in Europe.
In the context of EAP, the company has strengthened its manufacturing and supply chain to enable the timely and safe delivery of MaaT013 to 38 stem cell transplant hospitals in six European countries: Austria, Belgium, France, Germany, Italy and Spain.
Dr. Michael Roski, a hematologist at the Nice Hospital in France, emphasized: “We are enrolling in EAP because there are no third-line treatment options for aGvHD patients who do not respond to corticosteroids or ruxolitinib.With EAP's easy steps, we are able to deliver MaaT013 within 48 hours of request. “This has changed our routine.” “It has been effective in treating patients with aGvHD and significantly improved their quality of life. The data presented at ASH We observed superior efficacy with more complete responses.”[2] It affects gastrointestinal aGvHD and has low toxicity when compared to other immunosuppressive drugs. ”
“I think the EAP process is very easy.” Shared by Dr. Alexander Schauwvlieghe, hematologist at AZ Sint-Jan Brugge AV Hospital in Belgium. “I am a strong supporter of gut microbiome-based therapies, such as MaaT013, that prioritize immune recovery in GvHD. This approach preserves patient immune function and reduces the risk of infectious complications and relapse. It will help you.”
A pivotal Phase 3 study (n=75) evaluating MaaT013 in patients with corticosteroid and ruxolitinib-resistant gastrointestinal aGvHD (ARES study – NCT04769895) is currently underway to confirm the EAP results It is.We previously shared a positive review by DSMB[3] The Phase 3 ARES trial showed a favorable benefit/risk ratio;High efficacy and low toxicity.”
EBMT 2024 Oral Presentation Details
About MaaT Pharma
MaaT Pharma, a leading clinical-stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Based on positive results, MaaT Pharma, which treats cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, is launching an open-label monotherapy for patients with acute GvHD. A phase 3 clinical trial has started. Phase 2 proof of concept. gutPrint, a powerful discovery and analysis platform®enables the identification of new disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company's microbiome ecosystem therapies are manufactured through standardized cGMP manufacturing and quality control processes to safely deliver microbiome diversity in liquid and oral formulations. MaaT Pharma benefits from the efforts of world-leading scientists and established relationships with regulatory authorities to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).
Forward-looking statements
All statements, other than statements of historical fact, contained in this press release regarding future events are (i) subject to change without notice and (ii) to factors beyond our control. These statements include words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” and “estimate.” May include, without limitation, any statement that precedes, follows, or contains these words. “,” “plan,” “project,” “will,” “could,” “likely,” “should,” “would,” “could,” and Other words and terms of similar meaning or its negative meaning. Forward-looking statements involve inherent risks and uncertainties that are beyond our control and may cause our actual results or performance to differ from any anticipated results or performance expressed or implied by such forward-looking statements. It can vary greatly.
[1] American Society of Hematology
[2] No evidence of aGvHD
[3] Data Safety Monitoring Committee
View source version on businesswire.com. https://www.businesswire.com/news/home/20240311819202/ja/
contact address
MaaT Pharma – Investor Information
Dr. Guillaume Debrose
Head of Investor Relations
+33 6 16 48 92 50
invest@maat-pharma.com
MaaT Pharma – Media Support
Pauline Richaud
Senior PR and Corporate Communications Manager
+33 6 14 06 45 92
media@maat-pharma.com
Trophic Communication – Corporate Communication
Jacob Verges or
Priscilia Perrin
+49 151 7441 6179
maat@trophic.eu